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Background: The cellular mechanism(s) underlying autism spectrum disorders (ASDs) are not completely
understood, but ASDs are thought to ultimately result from disrupted synaptogenesis. However, studies have also
shown that glial cell numbers and function are abnormal in post-mortem brain tissue from autistic patients. Direct
assessment of glial cells in post-mortem human brain tissue is technically challenging, limiting glial research in
human ASD studies. Therefore, we attempted to determine if glial cell-type specific markers may be altered in
autistic brain tissue in a manner that is consistent with known cellular findings, such that they could serve as a
proxy for glial cell numbers and/or activation patterns.
Methods: We assessed the relative expression of five glial-specific markers and two neuron-specific markers via
qRT-PCR. We studied tissue samples from the prefrontal cortex (PFC) and cerebellum of nine post-mortem autistic
brain samples and nine neurologically-normal controls. Relative fold-change in gene expression was determined
using the ΔΔCt method normalized to housekeeping gene β-actin, with a two-tailed Student’s t-test P <0.05
between groups considered as significant.
Results: Both astrocyte- and microglial-specific markers were significantly more highly expressed in autistic PFC as
compared to matched controls, while in the cerebellum only astrocyte markers were elevated in autistic samples. In
contrast, neuron-specific markers showed significantly lower expression in both the PFC and cerebellum of autistic
patients as compared to controls.
Conclusions: These results are in line with previous findings showing increased glial cell numbers and
up-regulation of glial cell gene expression in autistic post-mortem brain tissue, particularly in the PFC, as well as
decreased number of neurons in both the PFC and cerebellum of autistic patients. The concordance of these
results with cell-level studies in post-mortem autistic brain tissue suggests that expression of glial cell-type
specific markers may serve as a useful alternative to traditional cellular characterization methods, especially
when appropriately-preserved post-mortem tissue is lacking. Additionally, these results demonstrate abnormal
glial-specific gene expression in autistic brains, supporting previous studies that have observed altered glial cell
numbers or activation patterns in ASDs. Future work should directly assess the correlation between cell-type
specific marker levels and cell number and activation patterns.
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Autism spectrum disorders (ASDs) are neurodevelop-
mental syndromes defined by impairments in language,
verbal and non-verbal communication, and restrictive/
repetitive patterns of behavior [1]. ASD symptoms mani-
fest within the first two years of life, with their severity
and presentation varying considerably between individ-
uals, thus yielding the ‘spectrum’ classification. ASDs are
estimated to affect 1 in 88 children in the United States,
and the prevalence of ASDs is at least four times more
common in males than females [2].
The etiology of autism is complex and the neurobio-
logical mechanism(s) that result in the clinical pheno-
type remain to be fully understood. However, there is
strong evidence that the autism phenotype ultimately
results from aberrant synaptic wiring in the developing
brain [3]. In particular, studies have shown that long-
distance communication between disparate neocortical
areas may be disrupted in ASDs, causing delays in infor-
mation processing within the brain that manifest as
the communication, language, and social development
problems seen in children with autism [4]. Additionally,
parallel research has shown that neuronal micro-
circuitry within brain areas may also be disrupted in
ASDs, and that this may result in local processing defi-
cits within brain regions related to higher functioning,
such as the prefrontal cortex (PFC) [5]. Underlying these
circuit disruptions is a large body of evidence that has
demonstrated decreased numbers of neurons (and their
various subtypes) throughout the autistic brain by early
childhood in post-mortem studies [6].
In addition to the body of evidence implicating
aberrant local and long-distance synaptic dysfunction in
ASDs, many studies have demonstrated microglial and
astrocyte dysfunction in ASD brains. For instance, post-
mortem pathological studies of autistic brain using
immunocytochemistry (IHC) and/or stereology have
identified microglial activation patterns [7-9], and have
demonstrated increased microglial cell density in mul-
tiple brain regions [8,10]. Glial activation refers to the
well characterized cascade of events that occurs upon
reaction of glia to stimuli, resulting in their mobilization,
release of cytokines, and ability to phagocytize, among
other processes [11]; glial activation is associated with
specific gene expression patterns that are distinct from
‘resting’ glial gene expression [12]. Furthermore, positron
emission tomography (PET) using a microglial-specific
radiotracer also demonstrated microglial activation in
multiple brain regions of autistic cases [13]. Additionally,
studies in a Rett syndrome mouse model, a single-gene
deletion disorder with autism as a component, have also
demonstrated cellular microglial abnormalities [14], and
a remarkable study demonstrated that autistic-like phe-
notypes can be partially reversed by replacing mutantMecp2 (−/−) microglia with their respective wild-type
cells [15].
Increased numbers of astrocytes, with altered cell size
and branching patterns, have also been demonstrated in
post-mortem autistic brains [16]. Additionally, astrocyte-
specific cell marker proteins are increased in multiple
autistic brain regions [17,18]. Similar to microglial stud-
ies in ASD mouse models, astrocytes have been shown
to be abnormal in a number of single-gene ASD models,
including Rett [19,20], Fragile X [21], and Tuberous
Sclerosis [22]. In parallel to the aforementioned microglial
study, it was also shown that replacing mutant astrocytes
in Mecp2 (−/−) mice can correct some aspects of the
phenotype [23].
However, it is not clear how these separate lines of
evidence—one demonstrating immune/glial dysfunction
in ASDs and the other implicating synaptic abnormal-
ities—may converge into a common mechanism in the
autistic brain that ultimately results in the shared clinical
phenotype. Because separate studies have shown that
microglia and astrocytes play critical roles in sculpting
developing synapses during normal neurodevelopment
[24,25], it is reasonable to hypothesize that inherent
defects or aberrant numbers of microglia and astrocytes
in the developing autistic brain may be causative of the
synaptic abnormalities by affecting the proper wiring of
developing neuronal connections. However, because
appropriately-preserved post-mortem autistic brain tis-
sue is lacking [26], cellular-level studies assessing glial
numbers and activation in human autistic brains have
been limited. Moreover, quantification of cell numbers
in postmortem tissue by stereology is technically chal-
lenging, further limiting the ability of researchers to
assess the few appropriately-preserved tissue samples
that are available. Finally, no studies have concurrently
specifically assessed for microglia, astrocytes, and neurons
in the same set of autistic brain samples. As a conse-
quence, a comprehensive understanding of the relation-
ship between glial and neuron cells in autistic brains is
needed.
Therefore, the purpose of this study was two-fold.
First, we sought to determine if microglia, astrocyte, and
neuron-specific markers were altered in post-mortem
autistic brain tissue, in order to further investigate the
role of glia in ASDs. Then, we determined if glial and
neuronal cell-type specific marker expression patterns
are consistent with known cellular-level findings, be-
cause gene expression studies of post-mortem human
brain are often easier to perform than cell-level studies,
and therefore this approach may serve as a valuable
‘screening’ assay to infer relative cell proportions.
In this study, we compared internally-normalized
mRNA expression levels of microglial, astrocyte, and
neuronal cell-type specific marker genes in post-mortem
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trols. Our results provide further evidence for a role of
glia in autism pathology, and suggest that assessment of
glial cell-type specific markers may serve as a proxy for
relative cellular numbers or activation patterns.
Methods
Post-mortem brain samples
Post-mortem brain tissue was obtained from the National
Institute of Child Health and Human Development Brain
and Tissue Bank, MD, USA. This source obtained consent
to use brain tissue for research from each patient or their
guardian prior to his/her death, and their protocol was
approved by their Institutional Review Board. No patient-
specific identifiable information was obtained. Because
multiple brain regions have been implicated in ASDs, we
performed our analysis in two separate areas that have
been consistently demonstrated as abnormal in autism—
the PFC and the cerebellum. We obtained post-mortem
PFC brain tissue from five individuals with autism and
from five healthy controls (Table 1). We obtained post-
mortem cerebellum brain tissue from four individuals
with autism and four healthy controls. The majority of
sample pairs (PFC and cerebellum) were derived from the
same donor brain. All cases were Caucasian males, and
case controls were matched by age as closely as possible.Table 1 Clinical characteristics and RNA quality of autistic and




1 5308* Autism PFC 4.5 Skull
2 1349 Autism PFC 5.6 Drow
3 5144 Autism PFC 7.2 Rhabd
4 5302* Autism PFC 16.3 DKA
5 4999* Autism PFC 20.8 Cardi
6 4670* Control PFC 4.6 Comm
7 1185 Control PFC 4.7 Drow
8 4898 Control PFC 7.7 Drow
9 4848* Control PFC 16.7 Drow
10 4727* Control PFC 20.5 Multip
11 5308* Autism Cere 4.5 Skull
12 4899 Autism Cere 14.3 Drow
13 5302* Autism Cere 16.3 DKA
14 4999* Autism Cere 20.8 Cardi
15 4670* Control Cere 4.6 Comm
16 4722 Control Cere 14.5 Multip
17 4848* Control Cere 16.7 Drow
18 4727* Control Cere 20.5 Multip
PFC: Prefrontal cortex; Cere: Cerebellum; UMB: University of Maryland Brain Bank sa
All-terrain vehicle; MVA: Motor vehicle accident; RIN: RNA integrity number. *Indicat
same donor brain.RNA isolation and quality control
RNA isolation and quality control analysis were
performed as previously described [27]. Briefly, total
RNA was extracted using TRIZOL Reagent (Life
Technologies, Carlsbad, CA, USA) according to the
manufacturer’s protocol. Quantification of RNA was
performed using a NanoDrop ND-1000, and RNA
integrity was assessed using an Agilent Bioanalyzer
2100 (Table 2).
Reverse transcriptase reaction
Total RNA (1 μg) was used in a 20 μL reverse transcript-
ase reaction to synthesize cDNA with SuperScript3
Reverse Transcriptase (Life Technologies) according to
the manufacturer’s protocol. Briefly, 1 μg of total RNA
was added to an aqueous solution containing 250 ng/μL
of random hexamer and 10 mM deoxyribonucleotide
triphosphate. The RNA was denatured for 5 minutes at
65°C and then snap cooled on ice for 2 minutes. After
which 0.1 M DTT, 5× First-Strand Buffer (250 mM
Tris–HCl, 375 mM KCl, 15 mM MgCl2), RNaseOUT
Recombinant Ribonuclease Inhibitor (40 Units/μL), and
SuperScript3 Reverse Transcriptase (200 Units/μL) were
added into each sample mixture. The reaction was
carried out under the following conditions: 25°C for 5
minutes, 50°C for 60 minutes, and 70°C for 15 minutes.control brain samples
e of PMI (h) RNA quality
A260/280 A260/230 RIN
fracture 21 2.051 2.266 4.9
ning 39 2.044 2.232 4.3
omyosarcoma 3 2.058 2.271 5.4
20 2.031 2.238 4
ac arrhythmia 14 2.039 2.232 6
otio Cordis 17 2.048 2.276 5.2
ning 17 2.026 2.243 4.7
ning 12 2.056 2.183 5.9
ning 15 2.044 2.185 6.7
le injuries (MVA) 5 2.066 2.209 6.5
fracture 21 2.087 1.781 7.3
ning 9 2.077 2.314 9.3
20 2.083 1.646 2.2
ac arrhythmia 14 2.081 2.114 9.2
otio Cordis 17 2.088 2.161 6.1
le injuries (ATV) 16 2.073 2.828 6.5
ning 15 2.087 2.327 6.8
le Injuries (MVA) 5 2.067 2.307 7.2
mple number; PMI: Post-mortem interval; DKA: Diabetic ketoacidosis; ATV:
es both prefrontal cortex and cerebellum samples were assessed from the
Table 2 Primers used for qRT-PCR
Primer name Primer sequence (5′ to 3′) OD MW % GC content Tm (°C)
ActinB-F AGAAAATCTGGCACCACACC 4.1 6064 50 60.4
ActinB-R AGAGGCGTACAGGGATAGCA 4.3 6240.1 55 62.4
Trem2-F CCGGCTGCTCATCTTACTCT 3.3 5995 55 62.4
Trem2-R AGTCATAGGGGCAAGACACC 4.2 6160 55 62.4
Dap12-F GAGACCGAGTCGCCTTATCA 3.8 6102 55 62.4
Dap12-R GTCATGATTCGGGCTCATTT 3.7 6114.1 45 58.4
Cx3cr1-F GCAGATCCAGAGGTTCCCTT 3.7 6093 55 62.4
Cx3cr1-R TAACAGGCCTCAGCCAAATC 3.9 6055 50 60.4
Gfap-F CTGCGGCTCGATCAACTCA 3.5 5748.8 57.9 62.3
Gfap-R TCCAGCGACTCAATCTTCCTC 3.6 6277.1 52.4 62.7
Nefl-F AGCTGGAGGACAAGCAGAAC 4.4 6209.1 55 62.4
Nefl-R TGCCATTTCACTCTTTGTGG 3.5 6065 45 58.4
Parvalbumin-F CTGGAGACAAAGATGGGGAC 4.3 6240.1 55 62.4
Parvalbumin-R CAGAGAGGTGGAAGACCAGG 4.4 6265.1 60 64.5
Aif1-F AGCAGTGATGAGGATCTGCC 4.0 6182.1 55 62.4
Aif1-R AGCATTCGTTTCAGGGACAT 3.9 6132.1 45 58.4
F: Forward; R: Reverse; OD: Optical density; MW: Molecular weight; Tm: Melting temperature.
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0.25× with nuclease free water.
Real time quantitative PCR
SYBR Green Expression Assay System (Applied Biosys-
tems, Foster City, CA, USA) was used to measure relative,
normalized, mRNA expression levels. We assessed four
separate microglial-specific cell surface genes: Triggering
receptor expressed on myeloid cells 2 (TREM2), DAP12,
CX3C chemokine receptor 1 (CX3CR1), and allograft
inflammatory factor 1 (AIF1) [28]. Two cell type spe-
cific intermediate filaments, glial fibrillary acidic pro-
tein (GFAP), which is astrocyte-specific [29], and the
pan-neuronal cell marker NEFL [30], were used to
assess for astrocytes and neurons, respectively. Add-
itionally, we assessed for GABAergic interneurons
specifically with parvalbumin (PVL) [31]. The intermedi-
ate filament housekeeping gene beta-actin (ACTB) was
used as a control. Forward and reverse primer sequences
were generated using Primer3 software and synthesized by
Eurofins MWG Operon (Huntsville, AL, USA) (Table 2).
Quantitative reverse transcriptase polymerase reaction
(qRT-PCR) was performed using an ABI Prism 7900 Se-
quence Detection System (Life Technologies) with a
96-well format. Each qRT-PCR reaction contained 6.5 μL
water, 12.5 μL SYBR Green master mix (Applied Biosys-
tems), 1 μL forward primer (10 μM), 1 μL reverse primer
(10 μM), and 4 μL of cDNA (0.25×). Data was collected
using the SDS2.3 Program (Applied Biosystems) under the
following run parameters: 48°C for 30 minutes, 95°C for10 minutes, 40 cycles of 95°C for 15 seconds, 60°C for 1
minute, and a final dissociation stage.
Data analysis
The target genes and the endogenous controls were
measured with technical triplicates in each qRT-PCR
reaction, and all genes were assessed in three separate,
independent qRT-PCR runs. The cycle threshold num-
ber (Ct) was calculated using RQ Manager 1.2 Software
(Applied Biosystems). Relative expression of each target
gene was normalized to ACTB using the ΔΔ Ct method.
All P values reported are based on a two-tailed Student’s
t-test. Only results with a P value less than 0.05 were
considered significant.
Results
The average post-mortem interval (PMI) was not sig-
nificantly different between autistic and control tissue
samples (Table 1; ASD = 17.9 h, ctrl = 13.2 h, P = 0.16).
This remained true after sub-stratifying by brain region
(ASD PFC = 19.4 h, ctrl PFC = 13.2 h, P = 0.28; and ASD
cerebellum = 16.0 h, ctrl cerebellum = 13.25 h, P = 0.48).
RNA isolated from post-mortem brain tissue was gener-
ally of high quality, and the RNA Integrity Number
(RIN) was not significantly different between autism and
controls (ASD = 5.84, ctrl = 6.18, P = 0.67). The RIN was
also not significantly different after sub-stratifying by
brain region (ASD PFC = 4.92, ctrl PFC = 5.80, P = 0.13;
and ASD cerebellum = 7.00, Ctrl cerebellum = 6.65,
P = 0.85).
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onstrated significantly increased expression in autistic
samples of TREM2, DAP12, and CX3CR1, but not AIF1
(Figure 1). The expression of TREM2 was highest of all
microglial markers, approximately 1.75-fold higher in
autism brain tissue than controls (P = 0.0016). The levels
of CX3CR1 and DAP12 were 1.50-fold (P = 0.0092) and
1.34-fold (P = 0.0086) higher in autistic samples relative
to controls, respectively. Similarly, the expression of
astrocyte marker GFAP was significantly higher in autis-
tic brains (1.70-fold, P = 0.0049). Conversely, however,
both the pan-neuronal marker NEFL, and the GABAer-
gic interneuron-specific marker PVA, were significantly
lower in autistic samples compared to controls (0.68-
fold, P = 0.0034; and 0.52-fold, P = 0.0020, respectively).
In post-mortem cerebellum, the expression of astro-
cyte marker GFAP was also significantly higher in autism
samples than in healthy controls (2.63-fold, P = 0.0022;
Figure 2). In contrast, the expression of microglial
markers TREM2, DAP12, CX3CR1, and AIF1 were lower
in autism tissue than in control tissue, with fold changes of
0.780 (P = 0.0056), 0.797 (P = 0.0083), 0.659 (P = 0.0029),
and 0.808 (P = 0.0052), respectively. Expression of neuronal
markers PVA and NEFL were also lower in autism samples
than in control samples (0.862-fold, P = 0.033; and 0.798-
fold, P = 0.013, respectively), as was found in the PFC.
Discussion
While there have been multiple studies assessing RNA
expression levels in autistic tissue, here we report on the
expression of microglial, astrocyte, and neuron-specific
cell markers concurrently in two regions of autistic
brains. Our results show that glial-specific markers
demonstrate altered expression in autistic brains. More-
over, the expression pattern of these cell-type specific
markers parallels previous findings of glial cell numberFigure 1 Expression of cell-type specific markers in prefrontal cortex
95% confidence intervals. *P <0.05, **P <0.005, n.s. = not significant.and activation patterns in autistic brain assessed via
cell-level techniques (discussed below). Therefore, this
approach may be a useful alternative for assessing
activation and/or cell numbers in post-mortem brain
tissue studies of ASD patients.
Microglia cell-marker research is still a relatively new
area, and thus the markers used to quantify microglial
cell number and activation are still debated. To address
this issue, we used four different markers that are
putatively microglial-specific. Our results demonstrate
that in the PFC, there is increased expression of all
microglial markers assessed, although AIF1 did not
reach statistical significance. However, previous reports
have shown that AIF1 expression in the brain is low
[32], potentially contributing to this result. The finding
of increased microglial cell markers in autistic PFC is in
agreement with a number of studies that have found in-
creased numbers and activation of microglia in autistic
brains. For instance, Morgan et al. showed increased
microglial density in dorsolateral PFC grey matter of
ASD brains via IHC and stereology [8], and they also
demonstrated that microglia are more closely associated
with neurons in autistic dorsolateral PFC than in con-
trols [9]. Similarly, Tetreault et al. also demonstrated
increased microglial density in the frontoinsular and
visual cortex of autistic brains as compared to controls
[10]. Additionally, a number of studies have specifically
identified microglial activation in autistic frontal cortex,
through both PET radiotracer imaging [13] and IHC/
cytokine profiling approaches [7]. Our results provide
further support to the growing body of evidence demon-
strating increased microglial numbers and activation in
autistic PFC, and our cell marker gene expression results
are largely in concordance with these cell level studies.
In contrast, our cerebellar results show significantly
lower expression of all four microglial cell specificsamples of autistic cases relative to controls. Error bars represent
Figure 2 Expression of cell-type specific markers in cerebellum samples of autistic cases relative to controls. Error bars represent
95% confidence intervals. *P <0.05, **P <0.005.
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identified microglial activation in the cerebellum of
autistic tissue [33], no study has attempted to specifically
quantify microglial cells in the cerebellum using the
markers assessed here, and therefore histopathologic
studies in the cerebellum are needed to confirm these
findings. One report described increased microglial cell
activation in the cerebellum, assessed via HLA-DR stain-
ing in the white matter and granular cell layer of the
cerebellum [7], and another showed increased microglial
activation throughout the brain (although most promin-
ently in the cerebellum) using an in vivo PET metabolic
radiotracer [13]. However, HLA-DR expression in
human microglial cells has been shown to be highly
variable between individuals, and its expression actually
decreases upon cytokine stimulation [34]. Moreover, as
we previously discussed [35], the cerebellum is anatom-
ically and physiologically unique; thus metabolic and
pathological findings in the cerebellum must be inter-
preted with caution. Furthermore, our tissue samples
from cerebellum contained all three layers of the cere-
bellar cortex, as opposed to the molecular layer only.
Until direct histologic assessment of these microglial
markers are performed in post-mortem autistic cerebel-
lum, our results must be interpreted cautiously. How-
ever, our results do suggest that there are significant
differences in microglial cell markers between ASD PFC
and cerebellum, perhaps reflecting differences in micro-
glial activation and/or cell numbers between these areas
in ASD brain.
In both the PFC and the cerebellum, there was signifi-
cantly increased expression of the astrocyte-specific
marker GFAP in autistic brains. This trend was most
prominent in the cerebellum, where GFAP expression
was over two-fold higher in ASD brains than in healthy
controls. Our findings parallel those of previous studies,which have shown increased expression of GFAP protein
in the cerebellum and cortex of patients of autism
through IHC staining, western blotting, and mRNA ex-
pression [7,17,36,37]. While studies have not been done
to quantify astrocyte numbers in the autistic cerebellum,
our results and those of previous studies provide evi-
dence for astroglial reaction in autism.
Interestingly, we also found significantly decreased
expression of the pan-neuronal marker NEFL in both
the PFC and the cerebellum of autistic brains. This
result is also supported by previous studies, which have
shown decreased NEFL mRNA expression in the anter-
ior cingulate gyrus, motor cortex, and thalamus of autis-
tic brains [38]. However, cell-level studies in autistic
brain have produced conflicting results about neuron
numbers. While a large body of evidence has suggested
there is a loss of neurons in many areas of autistic
brains, as recently reviewed in [39], other studies have
shown that young autistic brains may have 70% more
neurons in the PFC [40]. Importantly, though, is the age
of the patient at time of death, as longitudinal studies
have suggested that early brain overgrowth in ASDs
quickly reverses to a phenotype of neuronal loss [41].
Consequently, the older age of patients in this study may
bias our findings towards the neuronal loss spectrum of
the disease.
Similarly, we found significant decreases in the GABAer-
gic interneuron-specific marker PVA in both the PFC and
cerebellum of autistic samples. Despite many studies
demonstrating decreased GABAergic components across
different areas of the autistic brain, as reviewed in [42], the
one pathological analysis of parvalbumin-positive interneu-
rons in ASD did not identify differences in the autistic
cerebellum [43]. However, this study only assessed the
molecular layer of the cerebellar cortex, whereas our tissue
samples contained all three layers. Additionally, while
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unchanged in the autistic posterior cingulate cortex and
fusiform gyrus [44], and increased in the autistic hippo-
campus [45], they have not been directly assessed in the
autistic PFC.
In addition to potentially serving as markers of glial
cell numbers and/or activation, many of the genes
assessed have specific putative biological relevance to
ASDs themselves. For instance, in brain, Dap12 (also
known as TYROBP) encodes a microglial-specific trans-
membrane signaling polypeptide [46]. The encoded
protein acts as an activating signal transduction element
with known roles in brain myelination and inflammation
[47]. Its receptor, TREM2, encodes a membrane protein
that functions in modulating the brain’s immune re-
sponse via production of constitutive cytokines, and is
critical for activating microglial phagocytosis [48]. Rare
mutations within these two genes have been associated
with Nasu-Hakola disease [49]. Nasu-Hakola disease is
characterized neurologically by new onset psychiatric
and cognitive symptoms in the fourth decade of life,
evolving to memory loss and cognitive decline resem-
bling Alzheimer’s disease [50]. Interestingly, single nu-
cleotide polymorphisms in this receptor pathway were
also recently linked to a significantly increased risk of
Alzheimer’s disease, and are thought to relate to the
inability of microglia to properly remove neurodegenera-
tive debris such as beta-amyloid [51]. It is intriguing to
speculate that defects in this same pathway in neurode-
velopmental disorders such as ASDs may also result in
defects in microglial phagocytosis, but in the develop-
mental context it is the inability to prune overabundant
synapses, as opposed to neurodegenerative debris, that
results in the behavioral phenotype.
Similarly, CX3CR1, also known as the fractalkine
receptor, encodes a protein receptor on the surface of
microglia that binds to the chemokine CX3CL1 (also
called fractalkine); fractalkine functions to induce micro-
glial migration and adhesion during phagocytosis [52].
This pathway was recently demonstrated to play a
critical role in the developing brain of mice allowing for
migration of microglia to their synaptic targets, where
phagocytosis and synaptic refinement occur. CX3CR1
knockout mice had more synapses on cortical neurons
than wild-type mice, and displayed subtle neurological
deficits [25].
AIF1, also known as IBA1, encodes a protein that is
consistently up-regulated in expression during microglial
activation, and therefore has been used to discriminate
between resting and activated microglia [53]. The AIF1
gene is located within the highly variable locus contain-
ing parts of the major histocompatibility complex, which
itself has been linked to ASDs and dysfunctional micro-
glia phagocytosis [54].Glial fibrillary acidic protein (GFAP) is an intermediate
filament protein that is expressed by astrocytes, and as
discussed above, has been previously shown to be up-
regulated in autistic brains as was also shown here.
Interestingly, decreased expression of GFAP has been
reported in other neurodevelopmental disorders, such as
Schizophrenia and bipolar disorder [55]. GFAP, like
all intermediated filament proteins, is important in
maintaining the cellular cytoskeleton in astrocytes.
The cytoskeleton plays a number of key functional
roles in addition to maintaining cell shape, including
inter-cellular communication, mitosis, and cellular mi-
gration during phagocytosis. Mutations in GFAP are
responsible for Alexander’s disease, a rare disorder
characterized by severe developmental delay, increased
head size, and seizures [56].
Overall, our findings demonstrate that the autistic
brain by mid-childhood has molecular changes consist-
ent with increased astrocyte expression and decreased
neuronal and interneuron expression in both the PFC
and cerebellum, with PFC-specific increased microglial
marker expression. Furthermore, the specific glial
molecules found to be abnormal in autistic brains are
intimately involved in glial mobilization and phagocyt-
osis pathways, they have previously been shown to be
critical for normal neurodevelopment, and are known
to be causative of other rare neurodevelopmental
phenotypes. These findings support the notion that a
complex interplay between glial dysfunction and
neurogenesis may underlie the clinical manifestations
of ASDs.
This study has a number of limitations of note. Fore-
most is the relatively modest sample size. Unfortunately,
post-mortem human brain research in general is ham-
pered by the lack of accessibility to tissue samples, and
pediatric samples in particular are scarce [26]. Therefore,
replication with a large number of samples will be
important. However, we chose qRT-PCR techniques in
this pilot study because of the increased sensitivity
compared to whole-genome microarray or sequencing
approaches, and therefore some aspects of the small
sample size limitation are addressed. Secondly, due to
the inter-individual heterogeneity of the brain, and in
the brain-banking methodologies used in distinguishing
areas of post-mortem brain tissue, it cannot be assumed
that all samples will derive from the exact same
anatomic site within the PFC or cerebellum; this limita-
tion is largely unavoidable. Lastly, the approach of using
cell-type specific marker expression as a proxy for cell
number and/or activation still needs verification, by
assessing them concurrently with traditional histopatho-
logic/stereology analysis. However, the concordance of
our results with previously published studies, and the
scarcity of appropriate ASD brain tissue and technical
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alternative ‘screening’ approach.
Conclusions
In summary, assessment of glial numbers and activation
in autism post-mortem brain research is hampered by the
scarcity of appropriately-preserved tissue, and the tech-
nical challenge of traditional stereotactic methods. We
show that glial and neuron cell-type specific markers have
mRNA expression patterns that parallel known cellular
aberrations in ASDs. Our results provide further evidence
that glial cells may play a role in the pathogenesis of
ASDs, and suggest that assessing for glial cell-type specific
marker expression may represent a viable approach to
relatively quantify glial cell patterns in ASD post-mortem
research.
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